New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
10:25 EDTDRRX, DRRX, PCRX, PCRXSummer Street's chief scientific officer holds analyst/industry conference call
Chief Scientific Officer Classen discusses Durect's (DRRX) Posidur for post-operative pain, its safety and whether it could be disruptive to Pacira Pharmaceuticals (PCRX) on an Analyst/Industry conference call to be held on January 8 at 11 am.
News For DRRX;PCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 19, 2015
16:33 EDTPCRXPacira announces new Exparel data
Subscribe for More Information
May 18, 2015
08:31 EDTDRRXDURECT announces positive results from DUR-928 Phase 1 study
DURECT announced that it has obtained positive results from a multi-dose Phase 1 clinical trial with an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program. DUR-928 is an endogenous, small-molecule, new chemical entity, which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. It may also play an important role in protecting against acute kidney injury and other types of acute organ injury. This Phase 1 trial was a single-site, randomized, double-blinded, placebo-controlled, multiple-ascending-dose study to evaluate the safety, tolerability, and pharmacokinetics of DUR-928 when orally administered once daily for 5 consecutive days to healthy volunteers. The 20-subject study evaluated DUR-928 in 2 consecutive 10-subject cohorts, the first receiving DUR-928 at a lower dose and the second at a higher dose. Following multiple dosing, DUR-928 was well-tolerated at both dose levels, with no clinically significant changes in vital signs, laboratory values or ECG parameters, no severe or serious drug-related adverse events reported and no subjects withdrawing from the study. Peak plasma concentrations achieved were at least 100-fold higher than endogenous levels, no accumulation in plasma concentrations were observed with repeat dosing, and dose related increases in plasma concentrations were observed with peak plasma concentration at approximately 2 6 hours after dosing.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use